Universal Technical Institute, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a standalone fourth-quarter filing. Financial comparisons are primarily with fiscal 2021.
Business context
UTI provides transportation and technical career training through 16 U.S. campuses, including UTI, MMI, NASCAR Tech and MIAT. It also offers manufacturer-specific training. Most programs combine online instruction with hands-on labs. The MIAT acquisition closed November 1, 2021; the Concorde healthcare-college acquisition closed after year-end, on December 1, 2022.
Financial results and liquidity
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Revenue | $418.8 million | $335.1 million | Up 25.0%; MIAT contributed $23.6 million |
| Operating income | $22.4 million | $14.9 million | Operating margin 5.3%, versus 4.4% |
| Net income | $25.8 million | $14.6 million | Net margin 6.1%, versus 4.3% |
| Net income available to common shareholders | $12.8 million | $5.7 million | Basic/diluted EPS: $0.39/$0.38, versus $0.17/$0.17 |
| Operating cash flow | $46.0 million | $55.2 million | Down $9.2 million |
| Capital expenditures | $79.5 million | $61.6 million | Included campus purchases, openings and program investments |
| Liquidity at year-end | $95.4 million | $133.8 million | Cash and cash equivalents plus held-to-maturity investments; down $38.4 million |
| Gross long-term debt | $68.1 million | $31.0 million | Two property-backed term loans; covenants reported as satisfied |
Operating expenses rose 23.8%, slower than revenue growth. Advertising expense increased to $51.5 million from $38.7 million. The tax benefit was $5.4 million, including a $12.1 million release of valuation allowance; this non-cash tax benefit materially supported reported net income. EBITDA, a non-GAAP measure, was $38.8 million versus $29.5 million.
Liquidity and financing after year-end changed materially: UTI established a $100 million, three-year revolving facility in November 2022 and drew $90 million on November 28 to support the Concorde acquisition. Concorde’s stated cash purchase price was $50 million, subject to working-capital adjustments.
Material changes versus FY2021
- Average full-time active enrollment increased 11.7% to 12,838; year-end enrollment rose 5.1% to 14,380. New student starts increased 2.7% to 13,374.
- Growth reflected higher enrollment, MIAT, new Austin and Miramar campuses, and higher revenue per student as the prior-year effects of COVID-related delays diminished.
- Cash used in investing increased substantially, mainly due to $79.5 million of property and equipment purchases, the MIAT acquisition and campus investments. The Lisle campus purchase was approximately $28.7 million in cash, alongside assumed debt that was subsequently refinanced.
- UTI recorded a $2.0 million impairment charge after changing the MIAT trade name’s useful life from indefinite to four years. Goodwill was not impaired.
- Operating cash flow fell despite higher earnings, partly reflecting working-capital movements, including lower deferred revenue and lease payments.
Outlook, risks and unusual items
- Management said existing cash, investments and operating cash flows were expected to meet working-capital, capital, commitment and growth needs through at least the next fiscal year. This statement preceded the Concorde closing and related revolver draw; the filing provides no numerical earnings or revenue guidance.
- Management planned to begin launching 15 additional programs from the second quarter of fiscal 2023, subject to regulatory approvals, and continued investment in EV training and blended learning.
- Funding concentration is significant: approximately 67% of FY2022 revenue on an ED cash basis came from Title IV programs and approximately 13% from veterans’ benefits. Regulatory, funding or eligibility changes could materially affect operations.
- The new 90/10 rule takes effect July 1, 2023. UTI said it did not expect material compliance impact based on its review, but the rule’s treatment of federal education assistance, including VA and DOD funds, is a key monitoring point.
- The CFPB requested information in January 2022 while assessing whether UTI is subject to its supervisory authority related to student lending. UTI had responded and was awaiting further guidance. The FTC separately sent UTI and other institutions a notice about education-marketplace consumer-protection laws; it did not allege a specific violation.
- Variable-rate term debt is partly hedged: swaps effectively fixed rates on 50% of each loan. Management disclosed that a 10% interest-rate increase on unhedged term-loan balances would raise annual interest expense by approximately $3.4 million.
- Other items to note include the $1.6 million gain on settlement of the Lisle campus lease, the $2.0 million MIAT intangible impairment, and the valuation-allowance release supporting the tax benefit. Preferred dividends were $5.2 million; the Series A preferred stock also carries voting rights and potential dilution upon conversion.
- UTI disclosed ordinary-course claims and regulatory matters but reported no material legal proceedings. It stated that potential losses could not currently be estimated.
Investor verification priorities
- Verify the sustainability of enrollment and revenue growth, including the portions attributable to MIAT, new campuses, pricing and post-COVID normalization.
- Assess whether underlying earnings and cash generation support reported net income, given the valuation-allowance release and other identified unusual items.
- Review liquidity, leverage, debt covenants and the effect of the $90 million revolver draw and Concorde integration on post-year-end finances.
- Monitor Title IV and VA funding exposure, 90/10 compliance under the new rule, accreditation and authorization requirements, and the CFPB’s pending supervisory guidance.
- Evaluate proprietary student-loan collectability: the filing reports $35.9 million of notes receivable and identifies collection-rate estimation as a critical audit matter.
- Consider Series A preferred stock rights, including voting influence, dividends and potential common-share dilution.